Kerry A. Loughran

486 total citations
18 papers, 353 citations indexed

About

Kerry A. Loughran is a scholar working on Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Kerry A. Loughran has authored 18 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Cardiology and Cardiovascular Medicine and 4 papers in Surgery. Recurrent topics in Kerry A. Loughran's work include Cardiovascular Conditions and Treatments (12 papers), Cardiac Valve Diseases and Treatments (4 papers) and Congenital Heart Disease Studies (3 papers). Kerry A. Loughran is often cited by papers focused on Cardiovascular Conditions and Treatments (12 papers), Cardiac Valve Diseases and Treatments (4 papers) and Congenital Heart Disease Studies (3 papers). Kerry A. Loughran collaborates with scholars based in United States, Belgium and Canada. Kerry A. Loughran's co-authors include Mark A. Oyama, Qinghong Li, Jan S. Suchodolski, Vicky K. Yang, S.J. Hermansky, Airiel M. Davis, Douglas A. Neptun, Andrew M. Hoffman, Kristen Thane and Hon‐Wing Leung and has published in prestigious journals such as Food and Chemical Toxicology, Cytokine and Journal of the American Heart Association.

In The Last Decade

Kerry A. Loughran

18 papers receiving 341 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerry A. Loughran United States 10 151 131 112 52 42 18 353
Na Zhao China 11 178 1.2× 95 0.7× 28 0.3× 44 0.8× 71 1.7× 41 455
Rong Xu China 10 66 0.4× 146 1.1× 71 0.6× 19 0.4× 35 0.8× 47 346
Adriana Ortega‐Hernández Spain 10 133 0.9× 76 0.6× 21 0.2× 32 0.6× 22 0.5× 22 300
Semra Özdemir Türkiye 13 61 0.4× 45 0.3× 77 0.7× 20 0.4× 24 0.6× 40 342
Appie H. Kleine Netherlands 6 182 1.2× 343 2.6× 160 1.4× 22 0.4× 57 1.4× 7 589
А. В. Понасенко Russia 11 91 0.6× 107 0.8× 17 0.2× 51 1.0× 109 2.6× 82 426
R.I. McConnell Ireland 8 128 0.8× 57 0.4× 44 0.4× 11 0.2× 24 0.6× 13 331
Elisabet Rodríguez‐Tomàs Spain 13 167 1.1× 37 0.3× 15 0.1× 45 0.9× 70 1.7× 26 381
L. Barbot France 10 69 0.5× 107 0.8× 78 0.7× 7 0.1× 40 1.0× 21 439
Shuhei Tanaka Japan 10 62 0.4× 186 1.4× 49 0.4× 12 0.2× 45 1.1× 84 461

Countries citing papers authored by Kerry A. Loughran

Since Specialization
Citations

This map shows the geographic impact of Kerry A. Loughran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry A. Loughran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry A. Loughran more than expected).

Fields of papers citing papers by Kerry A. Loughran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry A. Loughran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry A. Loughran. The network helps show where Kerry A. Loughran may publish in the future.

Co-authorship network of co-authors of Kerry A. Loughran

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry A. Loughran. A scholar is included among the top collaborators of Kerry A. Loughran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry A. Loughran. Kerry A. Loughran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Loughran, Kerry A., et al.. (2024). Utility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine. 38(3). 1325–1333. 2 indexed citations
2.
Loughran, Kerry A., et al.. (2024). Observed and expected reliability of echocardiographic volumetric methods and critical change values for quantification of mitral regurgitant fraction in dogs. Journal of Veterinary Internal Medicine. 38(6). 3016–3024. 1 indexed citations
3.
Loughran, Kerry A., et al.. (2023). Urine sodium concentration after intravenous furosemide in dogs with acute congestive heart failure and correlation with treatment efficacy. Journal of Veterinary Internal Medicine. 38(1). 71–80. 2 indexed citations
4.
Shelton, G. Diane, et al.. (2021). Congenital dyserythropoiesis and polymyopathy without cardiac disease in male Labrador retriever littermates. Journal of Veterinary Internal Medicine. 35(5). 2409–2414. 3 indexed citations
5.
Loughran, Kerry A.. (2021). Focused Cardiac Ultrasonography in Cats. Veterinary Clinics of North America Small Animal Practice. 51(6). 1183–1202. 5 indexed citations
6.
Li, Qinghong, et al.. (2021). Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease. Journal of the American Heart Association. 10(9). e018923–e018923. 29 indexed citations
7.
8.
Loughran, Kerry A., et al.. (2020). Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. Journal of Veterinary Internal Medicine. 35(1). 22–32. 9 indexed citations
9.
10.
Loughran, Kerry A., et al.. (2020). Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease. Journal of Veterinary Internal Medicine. 35(1). 33–42. 20 indexed citations
11.
Loughran, Kerry A., et al.. (2020). Prediction and measurement of diuretic responsiveness after oral administration of furosemide to healthy dogs and dogs with congestive heart failure. Journal of Veterinary Internal Medicine. 34(6). 2253–2264. 6 indexed citations
12.
Oyama, Mark A., et al.. (2020). Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms. Cardiovascular Pathology. 46. 107196–107196. 42 indexed citations
13.
Loughran, Kerry A., et al.. (2019). The use of focused cardiac ultrasound to screen for occult heart disease in asymptomatic cats. Journal of Veterinary Internal Medicine. 33(5). 1892–1901. 22 indexed citations
14.
Loughran, Kerry A., Mark A. Oyama, Melissa D. Sánchez, et al.. (2019). Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease. Journal of Veterinary Internal Medicine. 33(4). 1571–1584. 29 indexed citations
15.
Loughran, Kerry A., et al.. (2019). Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease. Journal of Veterinary Internal Medicine. 33(2). 489–498. 25 indexed citations
16.
Yang, Vicky K., et al.. (2017). Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model. Journal of Extracellular Vesicles. 6(1). 1350088–1350088. 64 indexed citations
17.
Das, Rituparna, Kerry A. Loughran, Charles Murchison, et al.. (2015). Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis. Cytokine. 78. 51–54. 13 indexed citations
18.
Hermansky, S.J., Douglas A. Neptun, Kerry A. Loughran, & Hon‐Wing Leung. (1995). Effects of polyethylene glycol 400 (PEG 400) following 13 weeks of gavage treatment in fischer-344 rats. Food and Chemical Toxicology. 33(2). 139–149. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Na Zhao Breakdown of academic impact, for papers by Rong Xu Breakdown of academic impact, for papers by Adriana Ortega‐Hernández Breakdown of academic impact, for papers by Semra Özdemir Breakdown of academic impact, for papers by Appie H. Kleine Breakdown of academic impact, for papers by А. В. Понасенко Breakdown of academic impact, for papers by R.I. McConnell Breakdown of academic impact, for papers by Elisabet Rodríguez‐Tomàs Breakdown of academic impact, for papers by L. Barbot Breakdown of academic impact, for papers by Shuhei Tanaka
Rankless by CCL
2026